UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 178

Sortiert nach

Clostridium epsilon toxin is excessive in multiple sclerosis and provokes multifocal lesions in mouse models

The Journal of clinical investigation, 2023-05, Vol.133 (9), p.1-3

Reder, Anthony T

2023

Link zum Volltext

Verfügbarkeit prüfen

Vitamin D and Multiple Sclerosis: A Comprehensive Review

Neurology and therapy, 2018-06, Vol.7 (1), p.59-85

2018

Link zum Volltext

Verfügbarkeit prüfen

Thoracic flexion provokes circumferential dysesthesia: A symptom of thoracic cord lesions in MS

Multiple sclerosis, 2021-06, Vol.27 (7), p.1008-1013

Reder, Anthony T

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

Lancet neurology, 2014-06, Vol.13 (6), p.545-556

2014

Link zum Volltext

Verfügbarkeit prüfen

Prolonged Interferon-Stimulated Gene and Protein Signatures in Multiple Sclerosis Induced by PEGylated IFN-β-1a Compared to Non-PEGylated IFN-β-1a

Journal of interferon & cytokine research, 2023-03, Vol.43 (3), p.108

2023

Link zum Volltext

Verfügbarkeit prüfen

How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms

Journal of interferon & cytokine research, 2014-08, Vol.34 (8), p.589

2014

Link zum Volltext

Verfügbarkeit prüfen

Novel biomarkers and interferon signature in secondary progressive multiple sclerosis

Journal of neuroimmunology, 2024-04, Vol.389, p.578328-578328, Article 578328

2024

Link zum Volltext

Verfügbarkeit prüfen

COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies

CNS drugs, 2021-03, Vol.35 (3), p.317-330

2021

Link zum Volltext

Verfügbarkeit prüfen

Dimethyl fumarate-induced changes in the MS lymphocyte repertoire: No need for subset monitoring

Neurology, 2019-04, Vol.92 (15), p.696

2019

Link zum Volltext

Verfügbarkeit prüfen

Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis

Ophthalmology (Rochester, Minn.), 2013-07, Vol.120 (7), p.1432-1439

2013

Link zum Volltext

Verfügbarkeit prüfen

Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment

PloS one, 2018-12, Vol.13 (12), p.e0209326-e0209326

2018

Link zum Volltext

Verfügbarkeit prüfen

Medications for Multiple Sclerosis and Risk of Malignancy: What Next?

Neurotherapeutics, 2021-07, Vol.18 (3), p.1650-1653

2021

Link zum Volltext

Verfügbarkeit prüfen

T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy

Multiple Sclerosis Journal, 2023-05, Vol.29 (6), p.648-656

2023

Link zum Volltext

Verfügbarkeit prüfen

Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management

JAMA neurology, 2015-01, Vol.72 (1), p.31

2015

Link zum Volltext

Verfügbarkeit prüfen

Immunomodulatory activity of interferon‐beta

Annals of clinical and translational neurology, 2014-08, Vol.1 (8), p.622-631

2014

Link zum Volltext

Verfügbarkeit prüfen

Interferon-β corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection

EBioMedicine, 2019-11, Vol.49, p.269-283

2019

Link zum Volltext

Verfügbarkeit prüfen

Validity of the Neurology Quality-of-Life (Neuro-QoL) measurement system in adult epilepsy

Epilepsy & behavior, 2014-02, Vol.31, p.77-84

2014

Link zum Volltext

Verfügbarkeit prüfen

Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)

CNS drugs, 2021-07, Vol.35 (7), p.743-767

2021

Link zum Volltext

Verfügbarkeit prüfen

Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial

Multiple sclerosis, 2022-04, Vol.28 (5), p.790-800

2022

Link zum Volltext

Verfügbarkeit prüfen

Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy

Epilepsy & behavior, 2018-03, Vol.80, p.331-336

2018

Link zum Volltext

Verfügbarkeit prüfen

Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature

Multiple sclerosis and related disorders, 2016-09, Vol.9, p.158-162

2016

Link zum Volltext

Verfügbarkeit prüfen

Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: Gene expression and protein profiles

Frontiers in neurology, 2023-04, Vol.14, p.1158487-1158487

2023

Link zum Volltext

Verfügbarkeit prüfen

Understanding humoral immunity and multiple sclerosis severity in Black, and Latinx patients

Frontiers in immunology, 2023-05, Vol.14, p.1172993-1172993

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 178

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(160)
Mit Volltextzugriff
(141)

Publikationsform

Sprache

Englisch
(178)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

Science & Technology
(122)
Life Sciences & Biomedicine
(117)
Humans
(112)
Neurosciences & Neurology
(84)
Clinical Neurology
(71)
Neurology
(59)
Female
(58)
Multiple Sclerosis
(55)
Adult
(52)
Male
(52)
Biological And Medical Sciences
(45)
Middle Aged
(41)
Neurosciences
(41)
Medical Sciences
(39)
Immunology
(29)
Multiple Sclerosis - Drug Therapy
(28)
Multiple Sclerosis - Immunology
(25)
Interferon-Beta - Therapeutic Use
(20)
Magnetic Resonance Imaging
(19)
Multiple Sclerosis, Relapsing-Remitting - Drug Therapy
(17)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clostridium epsilon toxin is excessive in multiple sclerosis and provokes multifocal lesions in mouse models

Vitamin D and Multiple Sclerosis: A Comprehensive Review

Thoracic flexion provokes circumferential dysesthesia: A symptom of thoracic cord lesions in MS

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

Prolonged Interferon-Stimulated Gene and Protein Signatures in Multiple Sclerosis Induced by PEGylated IFN-β-1a Compared to Non-PEGylated IFN-β-1a

How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms

Novel biomarkers and interferon signature in secondary progressive multiple sclerosis

COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies

Dimethyl fumarate-induced changes in the MS lymphocyte repertoire: No need for subset monitoring

Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis

Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial

Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment

Medications for Multiple Sclerosis and Risk of Malignancy: What Next?

T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy

Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management

Immunomodulatory activity of interferon‐beta

Interferon-β corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection

Validity of the Neurology Quality-of-Life (Neuro-QoL) measurement system in adult epilepsy

Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial

Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy

Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature

Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: Gene expression and protein profiles

Understanding humoral immunity and multiple sclerosis severity in Black, and Latinx patients

Suchergebnisse filtern